Change over period: —
NSE · MEDICAMEQ
MEDICAMEN BI
-30.3% from the 52-week high · +31.8% above the low
Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is engaged in manufacturing pharmaceutical formulations products. The firm manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The firm is primarily focused on oncology therapeutics. The firm is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. The firm's oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, Nilotinib HCI, Oxaliplatin, Pazopanib, Pomalidomide and Tegafur. The firm has two manufacturing plants at Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The firm's wholly owned subsidiary is OPAL Pharmaceuticals Pty Ltd.
The short version. MEDICAMEN BI reported revenue of ₹48 crore for Jun 2026, up 11.6% from a year earlier. Net profit was ₹2 crore (up 0.0% year on year). Return on equity was 3.5% in Mar 2026. Promoter holding was 40.46% in Sep 2026, down 2.53 points over 8 quarters.
1 · The price
How has the stock traded?
MEDICAMEN BI trades 30.3% below its 52-week high and 31.8% above its 52-week low.
2 · The business
Is it growing?
Jun 2026 revenue of ₹48 cr.
Jun 2026 net profit of ₹2 cr.
0.6 pts lower than a year earlier.
Revenue compounded at 11.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48 | 61 | 47 | 47 | 43 | 30 | 45 | 45 |
| Net profit | 2 | 4 | 2 | 3 | 2 | 2 | 3 | 1 |
| Net margin % | 4.4 | 6.4 | 4.7 | 5.7 | 5.0 | 8.2 | 6.5 | 3.3 |
| EPS (₹) | 1.56 | 2.84 | 1.61 | 1.97 | 1.59 | 1.9 | 2.3 | 1.15 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 198 | 163 | 179 | 141 | 115 | 113 | 126 |
| Net profit | 10 | 7 | 11 | 15 | 15 | 12 | 13 |
| Net margin % | 4.9 | 4.4 | 6.1 | 10.5 | 12.9 | 10.8 | 10.6 |
| EPS (₹) | 7.11 | 5.59 | 8.64 | 11.73 | 12.19 | 9.93 | 10.88 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 3.5% in Mar 2026; debt to equity is 0.17.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 3.5 | 3.3 | 5.5 | 7.7 |
| Return on capital % | 5.5 | 6.0 | 8.6 | 10.2 |
| EBITDA margin % | 11.3 | 11.9 | 13.5 | 18.4 |
| Net margin % | 4.8 | 4.2 | 6.0 | 10.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 11.9% | 12.1% |
| Profit CAGR | -13.4% | -4.5% |
4 · The owners
Who holds it, and are they adding?
Down 2.53 pts over 8 quarters.
Up 4.44 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 42.99 | 43.16 | 40.46 | 40.46 | 40.46 | 40.46 | 40.46 | 40.46 | -2.53 |
| FII | 0.05 | 0.12 | 0 | 0.06 | 0.02 | 0.1 | 0.07 | 4.49 | +4.44 |
| DII | 0.87 | 0.69 | 0.64 | 0.59 | 0.44 | 0 | 0.4 | 0 | -0.87 |
| Public | 56.04 | 55.98 | 58.84 | 58.85 | 59.03 | 59.39 | 59.02 | 55.0 | -1.04 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.01% of NAV
- Bandhan BSE Healthcare Index Fund0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MEDICAMEN BI are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about MEDICAMEN BI
What is the MEDICAMEN BI share price?
MEDICAMEN BI (MEDICAMEQ) last closed at ₹287.40, down 0.81% on the day. Its 52-week range is ₹219.88 to ₹415.95.
What is the market cap of MEDICAMEN BI?
MEDICAMEN BI has a market capitalisation of about ₹396 crore. Its price-to-earnings ratio is 30.6.
How are MEDICAMEN BI's latest results?
MEDICAMEN BI reported revenue of ₹48 crore for Jun 2026, up 11.6% from a year earlier. Net profit was ₹2 crore (up 0.0% year on year). Return on equity was 3.5% in Mar 2026. Promoter holding was 40.46% in Sep 2026, down 2.53 points over 8 quarters.
Who owns MEDICAMEN BI?
As of Sep 2026, shareholding was: Promoter 40.46%, FII 4.49%, Public 55.0%.
How many mutual funds hold MEDICAMEN BI?
2 mutual fund schemes held MEDICAMEN BI in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 19 Sep 2025 · Final Dividend - Rs. 1
- 19 Sep 2024 · Final Dividend - Rs. 1
- 20 Sep 2023 · Final Dividend - Rs. 1
- 19 Sep 2022 · Final Dividend - Rs. 1
- 16 Sep 2021 · Final Dividend - Rs. 1
- 17 Sep 2020 · Final Dividend - Rs. 0.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.